Pacific Biosciences of California PACB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 37.5%+21.3pp | 28.6%+4.4pp | 25.4%+4.2pp | 21.4%-2.3pp | 16.2%-10.9pp | |
| Operating margin | -83.3%+456pp | -346.2%-38.2pp | -430.6%-195pp | -442.6%-216pp | -539.4%-378pp | |
| Net margin | -80.3%+353pp | -341.5%-139pp | -327.3%-99.6pp | -338.7%-127pp | -433.3%-285pp | |
| EBITDA margin | -74.5%+201pp | -107.1%+174pp | -179.4%+32.9pp | -188.9%+19.2pp | -275.2%-127pp | |
| Free cash flow margin | -72.6%+44.3pp | -71.2%+66.6pp | -81.7%+56.7pp | -97.6%+40.6pp | -116.9%+7.4pp | |
| Returns | ||||||
| Return on equity | -273.6%-95.3pp | -213.5%-162pp | -206.9%-142pp | -190.8%-120pp | -178.3%-134pp | |
| Return on assets | -15.6%+36.5pp | -53.4%-32.7pp | -44.9%-21.4pp | -45.3%-21.4pp | -52.2%-35.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×+0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Inventory turnover | 1.2×-0.5× | 1.4×-0.3× | 1.5×-0.5× | 1.6×-0.5× | 1.7×-0.6× | |
| Liquidity | ||||||
| Current ratio | 5.7×-1.0× | 5.1×-2.3× | 6.2×-3.5× | 6.9×-1.1× | 6.7×-2.6× | |
| Quick ratio | 4.4×-1.0× | 4×-2.2× | 4.9×-3.7× | 5.5×-1.7× | 5.4×-2.9× | |
| Cash ratio | 0.9×0.0× | 0.9×0.0× | 0.9×-0.4× | 0.9×-0.4× | 0.9×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 25.1×+24.5× | 10.7×+10.6× | 1.5×+1.5× | 0.9×+0.8× | 0.6×+0.5× | |
| Debt-to-assets | 0.1×0.0× | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -19.2×+51.9× | -79.6×-44.3× | -83.5×-54.8× | -70.7×-40.8× | -71×-48.3× | |
| Per Share | ||||||
| Book value per share | $0.01-97.5% | $0.02-99.0% | $0.12-92.8% | $0.20-88.7% | $0.31-87.2% | |
| Valuation | ||||||
| Market capitalization | $496.96M+30.4% | $564.57M+4.8% | $384.47M-17.0% | $360.1M-2.5% | $351.47M-64.9% | |
| Enterprise value | $498.38M+33.5% | $556.35M+10.0% | $381.1M-7.2% | $356.25M+18.9% | $343.63M-64.2% | |
| Price / sales | 3.1×+0.6× | 3.5×0.0× | 2.5×-0.2× | 2.3×+0.4× | 2.3×-2.7× | |
| Price / book | 210×+206× | 105.5×+104× | 10.7×+9.6× | 5.9×+5.1× | 3.8×+2.3× | |
| EV / sales | 3.1×+0.7× | 3.5×+0.2× | 2.5×+0.1× | 2.3×+0.7× | 2.3×-2.5× | |
| Free cash flow yield | -23.4%+23.4pp | -20.2%+19.2pp | -32.8%+18.9pp | -42.3%+28.3pp | -50.7%-25.8pp | |
| Earnings yield | -25.9%+147pp | -96.8%-38.8pp | -131.6%-46.5pp | -146.8%-38.4pp | -187.8%-158pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pacific Biosciences of California's profit margins?
- Pacific Biosciences of California (PACB) runs a 37.5% gross margin and a -83.3% operating margin, with a -80.3% net margin.
- Where do Pacific Biosciences of California's ratios come from?
- Every ratio is computed from Pacific Biosciences of California's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
